Invited SubmissionCutting Edge: Topical Recombinant Nerve Growth Factor for the Treatment of Neurotrophic Keratopathy—Biologicals as a Novel Therapy for Neurotrophic KeratopathyHamrah, Pedram MD*,†; Yavuz Saricay, Leyla MD*,†; Ozmen, M. Cuneyt MD† Author Information *Cornea Service, New England Eye Center, Department of Ophthalmology, Tufts Medical School, Tufts University School of Medicine, Boston, MA; and †Center for Translational Ocular Immunology, Department of Ophthalmology, Tufts Medical Center, Tufts University School of Medicine, Boston, MA. Correspondence: Pedram Hamrah, MD, Cornea Service, Tufts Medical Center, Tufts University School of Medicine, 800 Washington St, Boston, MA 02111 (e-mail: [email protected]). NIH R61-NS113341 (P. Hamrah), Massachusetts Lions Eye Research Fund Inc. (P. Hamrah), Bettingen Foundation (P. Hamrah), Lions Club International Foundation, Research to Prevent Blindness Challenge Grant, and Tufts Medical Center Institutional Support. The remaining authors have no conflicts of interest to disclose. The authors have no conflicts of interest to disclose. P. Hamrah and L. Yavuz Saricay contributed equally to this study. Cornea: June 2022 - Volume 41 - Issue 6 - p 673-679 doi: 10.1097/ICO.0000000000002974 Buy Metrics Abstract Ophthalmologists find management of neurotrophic keratopathy (NK) challenging because conventional therapy lacks efficacy and may result in permanent loss of vision. Recombinant nerve growth factor (cenegermin) targets the underlying pathogenesis of NK by regenerating corneal nerves and healing the corneal epithelium through promotion of proliferation, maturing corneal epithelial cells. It has been approved as Food Drug Association-approved treatment of NK. In this article, the background, clinical trials, and impact of recombinant nerve growth factor as the first neurotrophic factor for the restoration of corneal integrity, homeostasis, and corneal nerve regeneration are discussed. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.